{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:51:24Z","timestamp":1791219084231,"version":"4.1.0"},"reference-count":178,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Resistant hypertension, defined as blood pressure that remains above goal despite using three or more antihypertensive medications, including a diuretic, affects a significant proportion of the hypertensive population and is associated with increased cardiovascular morbidity and mortality. Despite the availability of a wide range of pharmacological therapies, achieving optimal blood pressure control in patients with resistant hypertension remains a significant challenge. However, recent advances in the field have identified several promising treatment options, including spironolactone, mineralocorticoid receptor antagonists, and renal denervation. In addition, personalized management approaches based on genetic and other biomarkers may offer new opportunities to tailor therapy and improve outcomes. This review aims to provide an overview of the current state of knowledge regarding managing resistant hypertension, including the epidemiology, pathophysiology, and clinical implications of the condition, as well as the latest developments in therapeutic strategies and future prospects.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1211199","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T07:56:44Z","timestamp":1687334204000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["When blood pressure refuses to budge: exploring the complexity of resistant hypertension"],"prefix":"10.3389","volume":"10","author":[{"given":"Meeti Keyur","family":"Champaneria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushi Sanjaykumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L.","family":"Oroszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e7473","DOI":"10.1136\/bmj.e7473","article-title":"Resistant hypertension","volume":"345","author":"Myat","year":"2012","journal-title":"Br Med J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American heart association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"B3","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2015.142","article-title":"Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension","volume":"88","author":"Sim","year":"2015","journal-title":"Kidney Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1161\/HYPERTENSIONAHA.108.114389","article-title":"Thiazide-induced dysglycemia","volume":"52","author":"Carter","year":"2008","journal-title":"Hypertension"},{"key":"B5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3949\/ccjm.90a.22046","article-title":"Resistant hypertension: a stepwise approach","volume":"90","author":"Yahr","year":"2023","journal-title":"Cleve Clin J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1161\/HYPERTENSIONAHA.114.03850","article-title":"Treatment-resistant hypertension and the incidence of cardiovascular disease and End-stage renal disease","volume":"64","author":"Muntner","year":"2014","journal-title":"Hypertension"},{"key":"B7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.amjmed.2013.07.038","article-title":"Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"key":"B11","doi-asserted-by":"publisher","first-page":"9606","DOI":"10.3390\/ijerph18189606","article-title":"Factors associated with medication non-adherence among patients with multimorbidity and polypharmacy admitted to an intermediate care center","volume":"18","author":"Gonz\u00e1lez-Bueno","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1161\/CIR.0b013e31821daaf6","article-title":"ACCF\/AHA 2011 expert consensus document on hypertension in the elderly","volume":"123","author":"Aronow","year":"2011","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1161\/HYPERTENSIONAHA.120.15300","article-title":"Effects of intensive versus standard office-based hypertension treatment strategy on white-coat effect and masked uncontrolled hypertension: from the SPRINT ABPM ancillary study","volume":"76","author":"Ghazi","year":"2020","journal-title":"Hypertension"},{"key":"B14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3109\/08037051.2014.883194","article-title":"The white-coat effect is an independent predictor of myocardial ischemia in resistant hypertension","volume":"23","author":"Modolo","year":"2014","journal-title":"Blood Press"},{"key":"B15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/jch.14218","article-title":"Clinical significance of nocturnal home blood pressure monitoring and nocturnal hypertension in Asia","volume":"23","author":"Fujiwara","year":"2021","journal-title":"J Clin Hypertens"},{"key":"B16","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"de la Sierra","year":"2011","journal-title":"Hypertension"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.116.08729","article-title":"Risk factors for nonadherence to antihypertensive treatment","volume":"69","author":"Gupta","year":"2017","journal-title":"Hypertension"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1161\/CIRCRESAHA.118.312156","article-title":"Treatment of resistant and refractory hypertension","volume":"124","author":"Acelajado","year":"2019","journal-title":"Circ Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension","volume":"58","author":"Bisognano","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.jacc.2017.11.004","article-title":"Systematic review for the 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"71","author":"Reboussin","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYP.0000000000000203","article-title":"Medication adherence and blood pressure control: a scientific statement from the American heart association","volume":"79","author":"Choudhry","year":"2022","journal-title":"Hypertension"},{"key":"B23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11906-015-0579-4","article-title":"Can drugs work in patients who do not take them? The problem of non-adherence in resistant hypertension","volume":"17","author":"Ruzicka","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s10865-010-9304-6","article-title":"Patient centered primary care is associated with patient hypertension medication adherence","volume":"34","author":"Roumie","year":"2011","journal-title":"J Behav Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.7399\/fh.10961","article-title":"Patient-centered prescription model to improve therapeutic adherence in patients with multimorbidity","volume":"42","author":"Gonz\u00e1lez-Bueno","year":"2018","journal-title":"Farm Hosp"},{"key":"B26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.mcna.2016.08.005","article-title":"Adherence to antihypertensive therapy","volume":"101","author":"Peacock","year":"2017","journal-title":"Med Clin N Am"},{"key":"B27","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/ajh\/hpaa085","article-title":"Cost-related antihypertensive medication nonadherence: action in the time of COVID-19 and beyond","volume":"33","author":"Tajeu","year":"2020","journal-title":"Am J Hypertens"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1001\/jama.299.16.1922","article-title":"Cost-related medication nonadherence and spending on basic needs following implementation of medicare part D","volume":"299","author":"Madden","year":"2008","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.118.313220","article-title":"Adherence in hypertension","volume":"124","author":"Burnier","year":"2019","journal-title":"Circ Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2147\/CIA.S113994","article-title":"The influence of frailty syndrome on medication adherence among elderly patients with hypertension","volume":"11","author":"Jankowska-Pola\u0144ska","year":"2016","journal-title":"Clin Interv Aging"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00049","article-title":"Hypertension and drug adherence in the elderly","volume":"7","author":"Burnier","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1001\/archinte.160.14.2101","article-title":"Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence","volume":"160","author":"DiMatteo","year":"2000","journal-title":"Arch Intern Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1590\/S1807-59322005000300010","article-title":"Hypertension and depression","volume":"60","author":"Scalco","year":"2005","journal-title":"Clinics"},{"key":"B34","first-page":"59","article-title":"New medication adherence scale versus pharmacy fill rates in seniors with hypertension","volume":"15","author":"Krousel-Wood","year":"2009","journal-title":"Am J Manag Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fphar.2013.00091","article-title":"Determinants of patient adherence: a review of systematic reviews","volume":"4","author":"Kardas","year":"2013","journal-title":"Front Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/pharmaceutics13071100","article-title":"Factors contributing to medication adherence in patients with a chronic condition: a scoping review of qualitative research","volume":"13","author":"Kvarnstr\u00f6m","year":"2021","journal-title":"Pharmaceutics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCULATIONAHA.108.830299","article-title":"Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients","volume":"120","author":"Mazzaglia","year":"2009","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s41043-015-0026-9","article-title":"Antiretroviral therapy adherence strategies used by patients of a large HIV clinic in Lesotho","volume":"33","author":"Axelsson","year":"2015","journal-title":"J Health Popul Nutr"},{"key":"B39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.12688\/f1000research.9692.1","article-title":"Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy","volume":"6","author":"Ghazi","year":"2017","journal-title":"F1000Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","article-title":"Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness","volume":"72","author":"Jia","year":"2018","journal-title":"Hypertension"},{"key":"B41","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1681\/ASN.2008040402","article-title":"Sympathetic activation in chronic renal failure","volume":"20","author":"Schlaich","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1525-1578(10)60624-1","article-title":"Angiotensin I-converting enzyme","volume":"2","author":"Crisan","year":"2000","journal-title":"J Mol Diagn"},{"key":"B44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"B45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/08998280.2003.11927893","article-title":"Angiotensin II receptor blockers","volume":"16","author":"Barreras","year":"2003","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1172\/JCI117786","article-title":"Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells","volume":"95","author":"Feener","year":"1995","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2008.10.029","article-title":"Aldosterone and mineralocorticoid receptors: clinical studies and basic biology","volume":"301","author":"Funder","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/hr.2011.105","article-title":"The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin\u2013angiotensin\u2013aldosterone system, oxidative stress and endogenous digitalis in the brain","volume":"34","author":"Takahashi","year":"2011","journal-title":"Hypertens Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1097\/HJH.0b013e3283375974","article-title":"A mechanism for salt-sensitive hypertension: abnormal dietary sodium-mediated vascular response to angiotensin-II","volume":"28","author":"Chamarthi","year":"2010","journal-title":"J Hypertens"},{"key":"B50","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.0711283105","article-title":"Impaired sodium excretion and increased blood pressure in mice with targeted deletion of renal epithelial insulin receptor","volume":"105","author":"Tiwari","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1524-6175.2006.06032.x","article-title":"Nitric oxide in hypertension","volume":"8","author":"Hermann","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1124\/pr.118.017129","article-title":"Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure","volume":"71","author":"Arendse","year":"2019","journal-title":"Pharmacol Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1586\/erc.09.127","article-title":"Recent changes in the landscape of combination RAS blockade","volume":"7","author":"Epstein","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11906-010-0118-2","article-title":"Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets","volume":"12","author":"F\u00e9l\u00e9tou","year":"2010","journal-title":"Curr Hypertens Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1074\/jbc.M603606200","article-title":"Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function","volume":"282","author":"Cardounel","year":"2007","journal-title":"J Biol Chem"},{"key":"B56","first-page":"99","article-title":"The relationship of stress and blood pressure effectors","volume":"19","author":"Ayada","year":"2015","journal-title":"Hippokratia"},{"key":"B57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ccl.2013.09.010","article-title":"The sympathetic nervous system and heart failure","volume":"32","author":"Zhang","year":"2014","journal-title":"Cardiol Clin"},{"key":"B58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11906-009-0084-8","article-title":"Chronic psychosocial stress and hypertension","volume":"12","author":"Spruill","year":"2010","journal-title":"Curr Hypertens Rep"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1161\/CIR.0b013e3181dbece1","article-title":"Particulate matter air pollution and cardiovascular disease","volume":"121","author":"Brook","year":"2010","journal-title":"Circulation"},{"key":"B60","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jacc.2008.05.029","article-title":"Air pollution and cardiovascular injury epidemiology, toxicology, and mechanisms","volume":"52","author":"Simkhovich","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1080\/10473289.2006.10464485","article-title":"Health effects of fine particulate air pollution: lines that connect","volume":"56","author":"Pope","year":"2006","journal-title":"J Air Waste Manage Assoc"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/ajh\/hpu071","article-title":"A review of evidence for the link between sleep duration and hypertension","volume":"27","author":"Gangwisch","year":"2014","journal-title":"Am J Hypertens"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/sleep\/30.12.1667","article-title":"Sleep duration as a risk factor for diabetes incidence in a large U.S. sample","volume":"30","author":"Gangwisch","year":"2007","journal-title":"Sleep"},{"key":"B64","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.118.11170","article-title":"Beyond resistant hypertension","volume":"72","author":"Mart\u00ednez-Garc\u00eda","year":"2018","journal-title":"Hypertension"},{"key":"B65","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1378\/chest.09-2954","article-title":"Sleep and hypertension","volume":"138","author":"Calhoun","year":"2010","journal-title":"Chest"},{"key":"B66","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/cdv.35.3.163.172","article-title":"Mental stress and its importance for cardiovascular disorders; physiological aspects, \u201cfrom-mice-to-man\u201d","volume":"35","author":"Folkow","year":"2001","journal-title":"Scand Cardiovasc J"},{"key":"B67","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1073\/pnas.0808358106","article-title":"From the cover: whole-genome association study identifies STK39 as a hypertension susceptibility gene","volume":"106","author":"Wang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B68","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1210\/er.2018-00071","article-title":"Genetics of human primary hypertension: focus on hormonal mechanisms","volume":"40","author":"Manosroi","year":"2019","journal-title":"Endocr Rev"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/578578","article-title":"Genetic and adverse health outcome associations with treatment resistant hypertension in GenHAT","volume":"2013","author":"Lynch","year":"2013","journal-title":"Int J Hypertens"},{"key":"B70","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0092-8674(92)90275-H","article-title":"Molecular basis of human hypertension: role of angiotensinogen","volume":"71","author":"Jeunemaitre","year":"1992","journal-title":"Cell"},{"key":"B71","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1161\/01.HYP.28.5.907","article-title":"Blood pressure and the M235T polymorphism of the angiotensinogen gene","volume":"28","author":"Hingorani","year":"1996","journal-title":"Hypertension"},{"key":"B72","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2174\/1874192401509010118","article-title":"Angiotensinogen (AGT) M235T, AGT T174M and angiotensin-1-converting enzyme (ACE) I\/D gene polymorphisms in essential hypertension: effects on ramipril efficacy","volume":"9","author":"Kolovou","year":"2015","journal-title":"Open Cardiovasc Med J"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/01.CIR.92.6.1387","article-title":"Angiotensin-converting enzyme in the human heart. Effect of the deletion\/insertion polymorphism","volume":"92","author":"Danser","year":"1995","journal-title":"Circulation"},{"key":"B74","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1445-5994.2011.02584.x","article-title":"Angiotensin-converting enzyme gene insertion\/deletion polymorphism and essential hypertension in the Chinese population: a meta-analysis including 21\u2003058 participants","volume":"42","author":"Li","year":"2012","journal-title":"Intern Med J"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/HYPERTENSIONAHA.112.196071","article-title":"Salt sensitivity of blood pressure is associated with polymorphisms in the sodium-bicarbonate cotransporter","volume":"60","author":"Carey","year":"2012","journal-title":"Hypertension"},{"key":"B76","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1177\/1470320311405873","article-title":"Renin gene polymorphism: its relationship to hypertension, renin levels and vascular responses","volume":"12","author":"Sun","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"B77","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1177\/1470320315584096","article-title":"Association of AT1R polymorphism with hypertension risk: an update meta-analysis based on 28,952 subjects","volume":"16","author":"Liu","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"B78","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jash.2013.12.001","article-title":"Modulation of aldosterone levels by -344 C\/T CYP11B2 polymorphism and spironolactone use in resistant hypertension","volume":"8","author":"Fontana","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"B79","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1161\/HYPERTENSIONAHA.121.16498","article-title":"Genetics of primary aldosteronism","volume":"79","author":"Scholl","year":"2022","journal-title":"Hypertension"},{"key":"B80","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1042\/CS20201287","article-title":"Epigenetic modifications of the renin-angiotensin system in cardiometabolic diseases","volume":"135","author":"Elgazzaz","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e40479","DOI":"10.1371\/journal.pone.0040479","article-title":"DNA Methylation analysis of the angiotensin converting enzyme (ACE) gene in major depression","volume":"7","author":"Zill","year":"2012","journal-title":"PLoS One"},{"key":"B82","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.3390\/ijms22094587","article-title":"DNA methylation of the angiotensinogen gene, AGT, and the aldosterone synthase gene, CYP11B2 in cardiovascular diseases","volume":"22","author":"Takeda","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/ng.922","article-title":"Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure","volume":"43","author":"Wain","year":"2011","journal-title":"Nat Genet"},{"key":"B84","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cardiores.2006.01.013","article-title":"Autonomic imbalance and immune activation in chronic heart failure\u2014pathophysiological links","volume":"70","author":"Jankowska","year":"2006","journal-title":"Cardiovasc Res"},{"key":"B85","doi-asserted-by":"publisher","first-page":"822","DOI":"10.4065\/84.9.822","article-title":"Sympathetic neural mechanisms in human cardiovascular health and disease","volume":"84","author":"Charkoudian","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"B86","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cphy.c150037","article-title":"Overview of the anatomy, physiology, and pharmacology of the autonomic nervous system","volume-title":"Comprehensive physiology","author":"Wehrwein","year":"2016"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","article-title":"The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications","volume":"54","author":"Triposkiadis","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1098725","DOI":"10.3389\/fimmu.2022.1098725","article-title":"Role of inflammation, immunity, and oxidative stress in hypertension: new insights and potential therapeutic targets","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"642416","DOI":"10.4061\/2011\/642416","article-title":"Pathophysiology of resistant hypertension: the role of sympathetic nervous system","volume":"2011","author":"Tsioufis","year":"2011","journal-title":"Int J Hypertens"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jch.13666","article-title":"The prevalence and predictors of resistant hypertension in high-risk overweight and obese patients: a cross-sectional study based on the 2017 ACC\/AHA guidelines","volume":"21","author":"Haddadin","year":"2019","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jch.12049","article-title":"Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the obesity society and the American society of hypertension","volume":"15","author":"Landsberg","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B92","doi-asserted-by":"publisher","first-page":"R803","DOI":"10.1152\/ajpregu.00707.2003","article-title":"Obesity and hypertension: two epidemics or one?","volume":"286","author":"Davy","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1161\/01.HYP.34.2.201","article-title":"Arterial stiffness and the development of hypertension. The ARIC study","volume":"34","author":"Liao","year":"1999","journal-title":"Hypertension"},{"key":"B94","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/039463201402700314","article-title":"Obesity, inflammation and endothelial dysfunction","volume":"28","author":"Iantorno","year":"2014","journal-title":"J Biol Regul Homeost Agents"},{"key":"B95","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1161\/CIRCULATIONAHA.106.650671","article-title":"Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice","volume":"115","author":"Gao","year":"2007","journal-title":"Circulation"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1172\/JCI117433","article-title":"Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release","volume":"94","author":"Steinberg","year":"1994","journal-title":"J Clin Invest"},{"key":"B97","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1161\/01.HYP.14.4.367","article-title":"Insulin and renal sodium retention in obese adolescents","volume":"14","author":"Rocchini","year":"1989","journal-title":"Hypertension"},{"key":"B98","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ejim.2012.04.012","article-title":"Resistant hypertension in visceral obesity","volume":"23","author":"Holecki","year":"2012","journal-title":"Eur J Intern Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1001\/archinternmed.2009.470","article-title":"Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study","volume":"170","author":"Blumenthal","year":"2010","journal-title":"Arch Intern Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1001\/jama.289.16.2083","article-title":"Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial","volume":"289","author":"Appel","year":"2003","journal-title":"JAMA"},{"key":"B101","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.HYP.0000244688.45472.95","article-title":"Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension","volume":"48","author":"Pojoga","year":"2006","journal-title":"Hypertension"},{"key":"B102","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/01.HYP.34.3.388","article-title":"Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension","volume":"34","author":"Fisher","year":"1999","journal-title":"Hypertension"},{"key":"B103","doi-asserted-by":"publisher","first-page":"324","DOI":"10.15585\/mmwr.mm6612a3","article-title":"Sodium intake among persons aged \u22652 years \u2014 united States, 2013\u20132014","volume":"66","author":"Quader","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B104","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5049\/EBP.2015.13.1.7","article-title":"Salt sensitivity and hypertension: a paradigm shift from kidney malfunction to vascular endothelial dysfunction","volume":"13","author":"Choi","year":"2015","journal-title":"Electrolyte Blood Press"},{"key":"B105","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/ndt\/15.3.441","article-title":"Salt intake and kidney disease","volume":"15","author":"Boero","year":"2002","journal-title":"J Nephrol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/HYPERTENSIONAHA.118.12074","article-title":"Reducing dietary sodium to 1000\u2005mg per day reduces neurovascular transduction without stimulating sympathetic outflow","volume":"73","author":"Babcock","year":"2019","journal-title":"Hypertension"},{"key":"B107","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3109\/03009734.2012.707253","article-title":"Obstructive sleep apnea syndrome (OSAS) and hypertension: pathogenic mechanisms and possible therapeutic approaches","volume":"117","author":"Zhang","year":"2012","journal-title":"Ups J Med Sci"},{"key":"B108","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11325-011-0481-5","article-title":"Epworth sleepiness scale may be an indicator for blood pressure profile and prevalence of coronary artery disease and cerebrovascular disease in patients with obstructive sleep apnea","volume":"16","author":"Feng","year":"2012","journal-title":"Sleep Breath"},{"key":"B109","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.111.179788","article-title":"Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension","volume":"58","author":"Pedrosa","year":"2011","journal-title":"Hypertension"},{"key":"B110","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4061\/2011\/340929","article-title":"Obstructive sleep apnea, hypertension, resistant hypertension and cardiovascular disease","volume":"4","author":"Jehan","year":"2020","journal-title":"Sleep Med Disord"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e1000132","DOI":"10.1371\/journal.pmed.1000132","article-title":"Sleep-disordered breathing and mortality: a prospective cohort study","volume":"6","author":"Punjabi","year":"2009","journal-title":"PLoS Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/675320","article-title":"Inflammatory markers in middle-aged obese subjects: does obstructive sleep apnea syndrome play a role?","volume":"2010","author":"Steiropoulos","year":"2010","journal-title":"Mediators Inflamm"},{"key":"B113","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1161\/HYPERTENSIONAHA.106.076190","article-title":"Sleep apnea and hypertension: interactions and implications for management","volume":"51","author":"Kapa","year":"2008","journal-title":"Hypertension"},{"key":"B114","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1161\/CIRCULATIONAHA.104.501841","article-title":"Obstructive sleep apnea syndrome affects left ventricular diastolic function","volume":"112","author":"Arias","year":"2005","journal-title":"Circulation"},{"key":"B115","doi-asserted-by":"publisher","first-page":"006","DOI":"10.17352\/2455-2976.000177","article-title":"Chaos, resistant and pseudoresistant hypertension \u201cthousands of butterflies in the BP control system\u201d","volume":"9","author":"Juan Carlos","year":"2022","journal-title":"J Cardiovasc Med Cardiol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/jch.14486","article-title":"Pseudo and resistant hypertension: a chaotic perspective","volume":"24","author":"Moreno","year":"2022","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2174\/1573402115666190301144316","article-title":"The adaptive value and clinical significance of allostatic blood pressure variation","volume":"15","author":"James","year":"2019","journal-title":"Curr Hypertens Rev"},{"key":"B118","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1038\/s41598-020-61562-6","article-title":"The control mechanisms of heart rate dynamics in a new heart rate nonlinear time series model","volume":"10","author":"He","year":"2020","journal-title":"Sci Rep"},{"key":"B119","doi-asserted-by":"publisher","first-page":"174","DOI":"10.29011\/2575-7083.100174","article-title":"Chaos a complex noise on blood pressure orchestration","volume":"7","author":"Dinamarco","year":"2022","journal-title":"Cardiolog Res Cardiovasc Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1471-2296-15-130","article-title":"The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review","volume":"15","author":"Lebeau","year":"2014","journal-title":"BMC Fam Pract"},{"key":"B121","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1751-7176.2008.08143.x","article-title":"Mechanisms and treatment of resistant hypertension","volume":"10","author":"Pimenta","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B122","doi-asserted-by":"publisher","first-page":"d286","DOI":"10.1136\/bmj.d286","article-title":"Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial","volume":"342","author":"Myers","year":"2011","journal-title":"Br Med J"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3390\/jcm11051455","article-title":"Rethinking resistant hypertension","volume":"11","author":"Bourque","year":"2022","journal-title":"J Clin Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1161\/HYPERTENSIONAHA.113.01275","article-title":"White-coat hypertension","volume":"62","author":"Franklin","year":"2013","journal-title":"Hypertension"},{"key":"B125","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/00126097-200112000-00016","article-title":"Task force II: blood pressure measurement and cardiovascular outcome","volume":"6","author":"Staessen","year":"2001","journal-title":"Blood Press Monit"},{"key":"B126","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.nefro.2020.12.020","article-title":"Masked hypertension: lessons for the future","volume":"89","author":"Penmatsa","year":"2020","journal-title":"Ulster Med J"},{"key":"B127","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1751-7176.2011.00445.x","article-title":"Epidemiology of resistant hypertension","volume":"13","author":"Sarafidis","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B128","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1161\/01.CIR.68.4.763","article-title":"Miscuffing: inappropriate blood pressure cuff application","volume":"68","author":"Manning","year":"1983","journal-title":"Circulation"},{"key":"B129","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/jhh.2013.140","article-title":"Apparent and true resistant hypertension: definition, prevalence and outcomes","volume":"28","author":"Judd","year":"2014","journal-title":"J Hum Hypertens"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"B131","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.pcad.2019.11.012","article-title":"Impact of therapeutic lifestyle changes in resistant hypertension","volume":"63","author":"Ozemek","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"key":"B132","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ahj.2015.08.006","article-title":"Lifestyle modification for resistant hypertension: the TRIUMPH randomized clinical trial","volume":"170","author":"Blumenthal","year":"2015","journal-title":"Am Heart J"},{"key":"B133","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3945\/an.115.009753","article-title":"Dietary patterns and blood pressure in adults: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Ndanuko","year":"2016","journal-title":"Adv Nutr"},{"key":"B134","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1017\/S136898000900531X","article-title":"Diet quality\u2014what is it and does it matter?","volume":"12","author":"Wirt","year":"2009","journal-title":"Public Health Nutr"},{"key":"B135","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1751-7176.2009.00136.x","article-title":"ASH position paper: dietary approaches to lower blood pressure","volume":"11","author":"Appel","year":"2009","journal-title":"J Clin Hypertens"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.numecd.2014.06.008","article-title":"Influence of dietary approaches to stop hypertension (DASH) diet on blood pressure: a systematic review and meta-analysis on randomized controlled trials","volume":"24","author":"Saneei","year":"2014","journal-title":"Nutr Metabol Cardiovascu Dis"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJM199704173361601","article-title":"A clinical trial of the effects of dietary patterns on blood pressure. DASH collaborative research group","volume":"336","author":"Appel","year":"1997","journal-title":"N Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ccl.2016.12.002","article-title":"The effects of dietary factors on blood pressure","volume":"35","author":"Appel","year":"2017","journal-title":"Cardiol Clin"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/advances\/nmaa041","article-title":"Dietary approaches to stop hypertension (DASH) diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Filippou","year":"2020","journal-title":"Adv Nutr"},{"key":"B140","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1741-7015-11-207","article-title":"Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial","volume":"11","author":"Toledo","year":"2013","journal-title":"BMC Med"},{"key":"B141","doi-asserted-by":"publisher","first-page":"8157858","DOI":"10.1155\/2020\/8157858","article-title":"Combined aerobic and resistance exercises evokes longer reductions on ambulatory blood pressure in resistant hypertension: a randomized crossover trial","volume":"2020","author":"Pires","year":"2020","journal-title":"Cardiovasc Ther"},{"key":"B142","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10741-014-9467-2","article-title":"Mineralocorticoid receptor antagonists as diuretics: can congestive heart failure learn from liver failure?","volume":"20","author":"Masoumi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/0002-9149(88)90551-6","article-title":"Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension","volume":"62","author":"Jeunemaitre","year":"1988","journal-title":"Am J Cardiol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(98)07614-4","article-title":"Optimisation of antihypertensive treatment by crossover rotation of four major classes","volume":"353","author":"Dickerson","year":"1999","journal-title":"Lancet"},{"key":"B145","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11906-015-0562-0","article-title":"Antihypertensive combination treatment: state of the art","volume":"17","author":"Burnier","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"B146","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am J Med"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1001\/archinte.1994.00420130048008","article-title":"A multifactorial trial design to assess combination therapy in hypertension","volume":"154","author":"Frishman","year":"1994","journal-title":"Arch Intern Med"},{"key":"B148","doi-asserted-by":"publisher","first-page":"131S","DOI":"10.1016\/S0895-7061(97)00101-5","article-title":"Combination antihypertensive therapy: does it have a role in rational therapy?","volume":"10","author":"Waeber","year":"1997","journal-title":"Am J Hypertens"},{"key":"B149","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0895-7061(99)00053-9","article-title":"Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension","volume":"12","author":"Kochar","year":"1999","journal-title":"Am J Hypertens"},{"key":"B150","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1080\/10641963.2019.1693586","article-title":"Efficacy and safety of a combination antihypertensive drug (olmesartan plus azelnidipine): \u201cissues with hypertension studies in real-world practice\u201d","volume":"42","author":"Okamura","year":"2020","journal-title":"Clin Exp Hypertens"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.jdiacomp.2016.04.020","article-title":"Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes\u2014network meta-analysis of randomized trials","volume":"30","author":"Remonti","year":"2016","journal-title":"J Diabetes Complications"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212531","article-title":"Combination therapy in the treatment of hypertension","volume":"7","author":"Guerrero-Garc\u00eda","year":"2018","journal-title":"Drugs Context"},{"key":"B153","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1536\/ihj.54.88","article-title":"Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension","volume":"54","author":"Yoshitomi","year":"2013","journal-title":"Int Heart J"},{"key":"B154","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/eurheartj\/ehx215","article-title":"Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: state of the art and considerations for the future","volume":"38","author":"Mahfoud","year":"2017","journal-title":"Eur Heart J"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study","volume":"373","author":"Krum","year":"2009","journal-title":"Lancet"},{"key":"B156","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(13)62192-3","article-title":"Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the symplicity HTN-1 study","volume":"383","author":"Krum","year":"2014","journal-title":"Lancet"},{"key":"B157","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1161\/CIRCULATIONAHA.112.130880","article-title":"Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the symplicity HTN-2 randomized, controlled trial","volume":"126","author":"Esler","year":"2012","journal-title":"Circulation"},{"key":"B158","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40292-018-0260-5","article-title":"Effectiveness of renal denervation in resistant hypertension: a meta-analysis of 11 controlled studies","volume":"25","author":"Pappaccogli","year":"2018","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"B159","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1093\/eurheartj\/eht154","article-title":"Expert consensus document from the European society of cardiology on catheter-based renal denervation","volume":"34","author":"Mahfoud","year":"2013","journal-title":"Eur Heart J"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED pivotal): a multicentre, randomised, sham-controlled trial","volume":"395","author":"B\u00f6hm","year":"2020","journal-title":"Lancet"},{"key":"B161","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.brs.2016.06.004","article-title":"Safety of transcranial direct current stimulation: evidence based update 2016","volume":"9","author":"Bikson","year":"2016","journal-title":"Brain Stimul"},{"key":"B162","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.neubiorev.2016.05.001","article-title":"A meta-analysis of non-invasive brain stimulation and autonomic functioning: implications for brain-heart pathways to cardiovascular disease","volume":"74","author":"Makovac","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2147\/CIA.S116194","article-title":"Transcranial direct current stimulation improves the QT variability index and autonomic cardiac control in healthy subjects older than 60 years","volume":"11","author":"Piccirillo","year":"2016","journal-title":"Clin Interv Aging"},{"key":"B164","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1469-7793.2000.t01-1-00633.x","article-title":"Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation","volume":"527","author":"Nitsche","year":"2000","journal-title":"J Physiol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.brs.2008.06.004","article-title":"Transcranial direct current stimulation: state of the art 2008","volume":"1","author":"Nitsche","year":"2008","journal-title":"Brain Stimul"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00641","article-title":"Transcranial direct current stimulation (tDCS): a beginner\u2019s guide for design and implementation","volume":"11","author":"Thair","year":"2017","journal-title":"Front Neurosci"},{"key":"B167","doi-asserted-by":"publisher","first-page":"e0187013","DOI":"10.1371\/journal.pone.0187013","article-title":"Preoperative transcranial direct current stimulation: exploration of a novel strategy to enhance neuroplasticity before surgery to control postoperative pain. A randomized sham-controlled study","volume":"12","author":"Ribeiro","year":"2017","journal-title":"PLoS One"},{"key":"B168","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.brs.2011.03.009","article-title":"Lack of clinically detectable acute changes on autonomic or thermoregulatory functions in healthy subjects after transcranial direct current stimulation (tDCS)","volume":"5","author":"Raimundo","year":"2012","journal-title":"Brain Stimul"},{"key":"B169","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neulet.2011.04.019","article-title":"Transcranial direct current stimulation influences the cardiac autonomic nervous control","volume":"497","author":"Montenegro","year":"2011","journal-title":"Neurosci Lett"},{"key":"B170","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.brs.2013.08.005","article-title":"Anodal transcranial direct current stimulation (tDCS) over the motor Cortex increases sympathetic nerve activity","volume":"7","author":"Clancy","year":"2014","journal-title":"Brain Stimul"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.853427","article-title":"Acute and short-term autonomic and hemodynamic responses to transcranial direct current stimulation in patients with resistant hypertension","volume":"9","author":"Rodrigues","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B172","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.mehy.2009.08.037","article-title":"Non-invasive brain stimulation for the management of arterial hypertension","volume":"74","author":"Cogiamanian","year":"2010","journal-title":"Med Hypotheses"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/eurheartj\/ehs368","article-title":"Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis","volume":"34","author":"Kumbhani","year":"2013","journal-title":"Eur Heart J"},{"key":"B174","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1751-7176.2011.00556.x","article-title":"Refractory hypertension: definition, prevalence, and patient characteristics","volume":"14","author":"Acelajado","year":"2012","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1097\/HJH.0b013e328353634e","article-title":"Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs","volume":"30","author":"de la Sierra","year":"2012","journal-title":"J Hypertens"},{"key":"B176","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","article-title":"Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the chronic renal insufficiency cohort study","volume":"67","author":"Thomas","year":"2016","journal-title":"Hypertension"},{"key":"B177","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/MNH.0b013e32834902ad","article-title":"Aging and antihypertensive medication-related complications in the chronic kidney disease patient","volume":"20","author":"Marcum","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B178","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11906-015-0578-5","article-title":"Quality of life in treatment-resistant hypertension","volume":"17","author":"Carris","year":"2015","journal-title":"Curr Hypertens Rep"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1211199\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T07:56:51Z","timestamp":1687334211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1211199\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":178,"alternative-id":["10.3389\/fcvm.2023.1211199"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1211199","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"article-number":"1211199"}}